Information  X 
Enter a valid email address

Verici Dx PLC (VRCI)

  Print   

Wednesday 25 May, 2022

Verici Dx PLC

Posting of Annual Report & Accounts

RNS Number : 7655M
Verici Dx PLC
25 May 2022
 

Verici Dx plc

("Verici Dx" or the "Company") 

 

Posting of Annual Report & Accounts

and
Notice of Annual General Meeting

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, confirms that the Annual Report and Accounts for the year ended 31 December 2021 ("2021 Annual Report") and the Notice of the 2022 Annual General Meeting ("AGM") have now been published on the Company's website: https://vericidx.com/investors/ .

 

The 2021 Annual Report, the Notice of AGM and details for voting by proxy will be posted to shareholders who have not consented to receive electronic communications today, on 25 May 2022.

 

The AGM is to be held at 3:00pm on 27 June 2022 at the Company's registered offices, at Avon House, 19 Stanwell Road, Penarth, Cardiff, CF64 2EZ and will consider the Resolutions set out in the Notice of AGM.

 

The Company is providing a facility for shareholders to listen in to the AGM either online or telephonically (in a non-voting capacity) and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Directors would request that shareholders register for the meeting and submit questions in advance, before 3:00pm on 24 June 2022. To register for dial-in details and to submit any questions please contact Walbrook PR via email at  [email protected] or call +44 (0)20 7933 8780.

 

Proxy voting

Shareholders will not receive a hard copy form of proxy for the 2022 AGM in the post. Instead, Shareholders will be able to vote electronically using the link  www.signalshares.com . Proxy votes must be received no later than 3:00pm on 23 June 2022.

 

Shareholders may request a hard copy form of proxy directly from the Registrars, Link Group, on Tel: 0371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales. Alternatively, shareholders can vote by downloading the new app, LinkVote+, on Apple App Store or Google Play and follow the instructions.

 

Enquiries:

 

Verici Dx

www.v ericidx .com

Sara Barrington, CEO 

Via Walbrook PR

Julian Baines, Chairman

 



Singer Capital Markets (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Kailey Aliyar / Rachel Hayes




Walbrook PR Limited

Tel: 020 7933 8780 or  [email protected]

Paul McManus / Sam Allen

Mob: 07980 541 893 / 07502 558 258

 

 

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.  The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.  The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAPPUWPAUPPUBA

a d v e r t i s e m e n t